Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

20-valent pneumococcal conjugate vaccine

Phase 1Vaccine

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Streptococcus PneumoniaeActive, not recruiting

Streptococcus PneumoniaePhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Streptococcus Pneumoniae

NCT07086677

Clinical

Trials by Indication[1]

Streptococcus Pneumoniae1 trial

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT07086677·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 20-valent pneumococcal conjugate vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 20-valent pneumococcal conjugate vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine
Highest Phase: Phase 1[1]
Company: Pfizer

Related News